文献速递心力衰竭与心肌病心律失常

非β阻滞R-对映体卡维地洛改善肥厚型心肌病心脏性能并减少心律失常

Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
PubMed 文献 · Circulation · 2023-10-18

该研究在肥厚型心肌病(HCM)细胞与小鼠模型中筛选21种β阻滞剂,发现R-卡维地洛通过双重抑制α1受体和RyR2,在不降低心率和心输出量的前提下抑制高动力收缩与心律失常,效果优于美托洛尔、维拉帕米和玛伐凯泰。

要点

  • R-卡维地洛保留抑制α1受体和RyR2的能力,无β阻滞效应。
  • 在HCM小鼠中R-卡维地洛使高动力收缩正常化并抑制心律失常。
  • R-卡维地洛增加心输出量优于美托洛尔、维拉帕米和玛伐凯泰。

核心结论

  • R-对映体卡维地洛通过双重阻断α1肾上腺素受体和RyR2,减轻高动力收缩、抑制心律失常并改善心输出量,且不降低心率。

研究设计与样本

  • 研究筛选21种β阻滞剂对心肌细胞收缩力的影响,并在心室肌细胞心律失常模型中评估候选药物的抗心律失常特性。
  • 通过血流动力学压力-容积环分析在体内检测左心室功能,并在Myh6R403Q/+小鼠HCM模型及患者iPSC来源心肌细胞(MYH7R403Q/+)中比较药物疗效。

主要发现

  • 卡维地洛通过抑制RyR2抑制收缩功能和心律失常,而美托洛尔(β1阻滞剂)无此作用。
  • R-卡维地洛在Myh6R403Q/+小鼠中使高动力收缩正常化、抑制心律失常并增加心输出量,效果优于美托洛尔、维拉帕米和玛伐凯泰。
  • R-卡维地洛抑制收缩功能的能力在MYH7R403Q/+ iPSC来源心肌细胞中得以保留。

临床怎么用

  • R-卡维地洛可能尤其获益于无左心室流出道梗阻的HCM患者,因其在抑制高动力收缩和心律失常的同时不降低心率和心输出量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypercontractility and arrhythmia are key pathophysiologic features of hypertrophic cardiomyopathy (HCM), the most common inherited heart disease. β-Adrenergic receptor antagonists (β-blockers) are the first-line therapy for HCM. However, β-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue. Mavacamten, myosin ATPase inhibitor recently approved by the US Food and Drug Administration, has demonstrated the ability to ameliorate hypercontractility without lowering heart rate, but its benefits are so far limited to patients with left ventricular (LV) outflow tract obstruction, and its effect on arrhythmia is unknown. METHODS: We screened 21 β-blockers for their impact on myocyte contractility and evaluated the antiarrhythmic properties of the most promising drug in a ventricular myocyte arrhythmia model. We then examined its in vivo effect on LV function by hemodynamic pressure-volume loop analysis. The efficacy of the drug was tested in vitro and in vivo compared with current therapeutic options (metoprolol, verapamil, and mavacamten) for HCM in an established mouse model of HCM (Myh6R403Q/+ and induced pluripotent stem cell (iPSC)-derived cardiomyocytes from patients with HCM (MYH7R403Q/+). RESULTS: We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2). Unlike metoprolol (a β1-blocker), carvedilol markedly reduced LV contractility through RyR2 inhibition, while maintaining stroke volume through α1-adrenergic receptor inhibition in vivo. Clinically available carvedilol is a racemic mixture, and the R-enantiomer, devoid of β-blocking effect, retains the ability to inhibit both α1-receptor and RyR2, thereby suppressing contractile function and arrhythmias without lowering heart rate and cardiac output. In Myh6R403Q/+ mice, R-carvedilol normalized hyperdynamic contraction, suppressed arrhythmia, and increased cardiac output better than metoprolol, verapamil, and mavacamten. The ability of R-carvedilol to suppress contractile function was well retained in MYH7R403Q/+ iPSC-derived cardiomyocytes. CONCLUSIONS: R-enantiomer carvedilol attenuates hyperdynamic contraction, suppresses arrhythmia, and at the same time, improves cardiac output without lowering heart rate by dual blockade of α1-adrenergic receptor and RyR2 in mouse and human models of HCM. This combination of therapeutic effects is unique among current therapeutic options for HCM and may particularly benefit patients without LV outflow tract obstruction.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Seo K, Yamamoto Y, Kirillova A, et al. Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. Circulation. 2023. PMID: 37850394. doi:10.1161/CIRCULATIONAHA.123.065017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。